18 hrs ago
Building Presence in World's Largest Biomedical Market
At its annual shareholders' meeting held yesterday in Dunedin, New Zealand, cancer diagnostic developer, Pacific Edge, celebrated the commercial launch of its flagship bladder cancer diagnostic product, Cxbladder, into the US and provided shareholders with an update on its growth plans.
23 hrs ago
Surgery associated with better survival for patients with advanced laryngeal cancer
Approximately 11,000 to 13,000 cases of laryngeal cancer are diagnosed each year and squamous cell carcinoma accounts for the vast majority of these tumors.
Arutz Sheva Israel News
Technology & HealthWoman's Cancer Drives Daughter to Research Breakthrough
Dr. Svetlana Bunimovich, lecturer in the Department of Computer Science and Mathematics at the University of Ariel, will present research done using mathematical models, to improve the treatment of bladder cancer, at a conference to be held at Ariel University next week .
Wed Aug 20, 2014
Validation of RiskCheck Bladder Cancera OEA , version 5.0 for...
The aim of the study was to assess the strength of the online tool RiskCheck Bladder CancerA©, version 5.0 for early detection of bladder cancer .
Largest cancer genomic study proposes 'disruptive' new system to reclassify tumors
TCGA scientists analyzed the DNA, RNA and protein from 12 different tumor types using six different TCGA "platform technologies" to see how the different tumor types compare to each other.
Tue Aug 19, 2014
Revealed: The most devastating failures by public services
Paul Gallagher is a reporter for the Independent and Independent on Sunday having joined the group in 2012.
Bioniche Life Sciences Inc. Announces Q1/2015 Timeline For The Filing ...
This projected timeline integrates the conclusions of a regulatory gap analysis prepared by its consultants with the planning and scheduling of a pre-BLA meeting between Bioniche and the FDA prior to the BLA filing.
Customer Interaction Solutions
Altor BioScience Awarded SBIR Phase II Grant by NCI for Clinical...
Altor BioScience Corporation , a leading developer of cancer immunotherapies, announced today that it has been awarded a Small Business Innovation Research Phase II grant by the National Cancer Institute for the clinical development of ALT-803, a proprietary interleukin-15 superagonist protein complex, against non-muscle invasive bladder cancer .
Sat Aug 16, 2014
Market Report, "Marina Biotech, Inc. (MRNA) - Pharmaceuticals &...
It develops and commercializes therapeutic products based on RNS interference and mRNA translational blocking.
Thu Aug 14, 2014
Father of newborn son struggling with aggressive cancer battle
A Northampton County dad needs your help. Just weeks after his son was born, he found out he has a rare and aggressive cancer.
Wed Aug 13, 2014
Could Hyaluronic acid (HA) reduce Bacillus Calmette-Guerin (BCG)...
Bacillus Calmette-Guerin is considered the most effective treatment to reduce recurrence and progression of non-muscle invasive bladder cancer but can induce local side effects leading to treatment discontinuation or interruption.
Tengion says regenerative kidney treatment trial on track
Tengion , the Winston-Salem biotech company working to commercialize some of the technologies developed by Dr. Anthony Atala and the Wake Forest Institute for Regenerative Medicine , said the Phase 1 clinical trial of its Neo-Kidney Augment is on track so far.
Clinical trial tests COXEN model to predict best treatment for bladder cancer
Imagine being able to match a cancer's genes to the best treatment. That's the promise of COXEN - a computer program that looks at a panel of cancer genes in a patient's tumor to predict whether it will respond to chemotherapy.
Tue Aug 12, 2014
New Albany Gazette
Bladder surgery and a priest
Jenny was prepared for the worst when she was wheeled into her room after bladder surgery at Baptist Memorial Hospital in Oxford and was met by a priest.
Global Urology Devices Market 2014-2018
About Urology Devices Urology devices are used for the diagnosis and treatment of disorders associated with male and female urinary tract systems and the male reproductive organs.
Mon Aug 11, 2014
Applied Clinical Trials
Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug ...
In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome .
Expression signature defined by FOXM1-CCNB1 activation predicts...
Clinical cancer research : an official journal of the American Association for Cancer Research , Vol.
Medical News Today
A new approach to classifying tumors
Researchers with The Cancer Genome Atlas have analyzed more than 3500 tumors on multiple genomic technology platforms, revealing a new approach to classifying cancers .
Fri Aug 08, 2014
WWL-TV New Orleans
Nearly 10% of cancer survivors smoke, despite risks
Smoking rates are especially high among those who had cancers strongly linked to smoking, such as lung and bladder cancer, say researchers who questioned nearly 3,000 survivors nine years after diagnosis.
Involvement of seladin-1 in goniothalamin-induced apoptosis in urinary bladder cancer cells
Selective Alzheimer Disease Indicator-1 is a multifunctional protein first discovered by downregulation of its expression in Alzheimer's disease.